23 results
F-1/A
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
terms. The Company may also face substantial fines and penalties and may incur damage to its reputation and standing in the community. Your conduct … a high value on its credibility and reputation in the community. What is written or said about the Company in the news media and investment community
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
10 Jun 22
Current report (foreign)
6:05am
of our product candidates by physicians, patients, healthcare payors and others in the medical community. These risks are not exhaustive
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Feb 22
Current report (foreign)
4:01pm
, patients, healthcare payors and others in the medical community. These risks are not exhaustive. The inclusion of forward-looking statements should
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
acceptance of our product candidates by physicians, patients, healthcare payors and others in the medical community. These risks are not exhaustive
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
product candidates by physicians, patients, healthcare payors and others in the medical community. These risks are not exhaustive. New risk factors … community. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors
CORRESP
btl7ra12
8 Mar 21
Correspondence with SEC
12:00am
6-K
EX-99.2
efqbh
5 Jan 22
Current report (foreign)
5:24pm
F-1/A
EX-10.4
wispud9 o792
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
EX-99.1
bz6n4au u9rh8pas6m03
5 Jun 23
Current report (foreign)
4:28pm
DRS/A
EX-10.5
q10u w4ogq1n
26 Jan 21
Draft registration statement (amended)
12:00am
F-1
EX-10.5
tehx5f4xw
26 Feb 21
Registration statement (foreign)
4:56pm
424B4
ug2g3mfu8evc67
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1
sd4t3chzp
26 Feb 21
Registration statement (foreign)
4:56pm
F-1/A
ljm fgiy04
18 Mar 21
Registration statement (foreign) (amended)
6:15am
DRS/A
zmkm41ztvup48 1roe15
26 Jan 21
Draft registration statement (amended)
12:00am
F-1/A
0vre8v
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
DRS
ebevo98rj
17 Dec 20
Draft registration statement
12:00am
20-F
sugrxij0tlhwijfr58z
31 Mar 22
Annual report (foreign)
4:33pm